Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...

Machine learning models using data from digital inhalers can successfully predict COPD exacerbations up to 5 days in advance.

Plumes of Saharan dust are expected to sweep over Florida in the coming days, which can cause real problems for people with respiratory issues.

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Topline results were announced from two phase 3 trials evaluating itepekimab, an anti-interleukin-33 monoclonal antibody, in former smokers with inadequately controlled chronic obstructive pulmonary ...

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not ...

The U.S. Food and Drug Administration (FDA) has approved GSK’s Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with chronic obstructive pulmonary disease (COPD) with ...

Using imaging and respiratory symptoms, researchers identified up to 15.4% of individuals without airflow obstruction as ...

Uncover the truth behind Breathe Supplement with our full reviews—learn if this herbal lung formula is safe, effective, and ...

However, not many people with COPD receive support that promotes the use of such strategies and therefore new methods to facilitate and promote the use of self-management strategies are highly ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

Breathe easier with this natural supplement. See how Breathe Drops aid in clearing airways and boosting lung function—plus ...